NCT05441267View on ClinicalTrials.gov

A Study of Cardiovascular Events iN Diabetes Plus

PHASE4RecruitingINTERVENTIONAL
Enrollment

20,000

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

August 17, 2028

Study Completion Date

August 17, 2048

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide Oral Tablet

Oral semaglutide 14mg daily (option to reduce to 7mg daily)

DRUG

Placebo oral tablet

Placebo oral semaglutide

Trial Locations (1)

Unknown

RECRUITING

Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Oxford

OTHER